Black Rock Inc. Cyclerion Therapeutics, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.43 - $0.9 $124 - $261	-290 Reduced 0.08%	360,016 $154,000
Q4 2022 Feb 13, 2023	SELL	$0.42 - $18.8 $155 - $6,956	-370 Reduced 0.1%	360,306 $237,000
Q3 2022 Nov 14, 2022	SELL	$0.58 - $18.2 $524 - $16,452	-904 Reduced 0.25%	360,676 $310,000
Q2 2022 Aug 12, 2022	SELL	$0.47 - $1.29 $37,506 - $102,942	-79,800 Reduced 18.08%	361,580 $198,000
Q1 2022 May 12, 2022	SELL	$0.96 - $1.78 $3,634 - $6,739	-3,786 Reduced 0.85%	441,380 $490,000
Q4 2021 Feb 10, 2022	BUY	$1.56 - $2.99 $15,617 - $29,932	10,011 Added 2.3%	445,166 $765,000
Q3 2021 Nov 09, 2021	SELL	$2.73 - $4.13 $2,708 - $4,096	-992 Reduced 0.23%	435,155 $1.34 Million
Q2 2021 Aug 11, 2021	BUY	$2.18 - $4.29 $950,800 - $1.87 Million	436,147 New	436,147 $1.7 Million

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $139M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.